| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 2006;82:1779-1783
© 2006 The Society of Thoracic Surgeons
a Department of Cardiothoracic Surgery, Mount Sinai Hospital, New York, New York
b Department of Anesthesiology, Mount Sinai Hospital, New York, New York
Accepted for publication May 16, 2006.
* Address correspondence to Dr Filsoufi, Department of Cardiothoracic Surgery, Mount Sinai Medical Center, 1190 Fifth Ave, Box 1028, New York, NY 10029 (Email: farzan.filsoufi{at}mountsinai.org).
BACKGROUND: Severe coagulopathy after cardiovascular surgery may lead to intractable bleeding and is associated with increased mortality and morbidity. Recent studies have suggested that recombinant activated factor VII (rFVIIa) may play a role in decreasing postoperative bleeding. Herein we report our experience with the off-label use of rFVIIa in patients with refractory postcardiotomy bleeding.
METHODS: From June 2003 to December 2005, 17 patients (mean age, 65 ± 18 years) received rFVIIa for refractory bleeding after cardiac surgery. Preoperative risk factors for bleeding included reoperation (n = 7), emergency surgery (n = 7), and renal or hepatic failure (n = 3). Surgical procedures were aortic surgery (n = 7), complex valve operations (n = 7), coronary artery bypass grafting (n = 2), and cardiac tumor resection (n = 1).
RESULTS: The average dose of rFVIIa was 103.1 ± 30.2 µg/kg. After the administration of rFVIIa the blood loss was reduced and chest tube output decreased from an average of 300 mL/h to 60 mL/h (p = 0.024). Coagulation variables normalized (mean prothrombin time, 18 ± 7 versus 14 ± 3 seconds; p = 0.03; mean partial thromboplastin time, 94 ± 50 versus 49 ± 14 seconds; p = 0.02), and the need for blood products was significantly reduced. Only 1 patient required mediastinal reexploration. No thromboembolic complications occurred during hospitalization.
CONCLUSIONS: This study suggests that rFVIIa is safe and efficacious in the management of refractory postcardiotomy bleeding. The use of rFVIIa is associated with reduced blood loss, rapid improvement of coagulation variables, and decreased need for blood products. Further studies are necessary to determine the safety and efficacy of this new hemostatic agent and its precise role in the treatment of severe postoperative coagulopathy.
This article has been cited by other articles:
|
|
 |
|
  A.-A. Alavi, S. M. Jalali, M. R. Rasouli, and P. Eghtesadi-Araghi Administration of Recombinant Activated Factor VII in Major Thoracic Operations Arch Surg, October 1, 2008; 143(10): 1021 - 1021. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Karkouti, W. S. Beattie, R. Arellano, T. Aye, J. S. Bussieres, J. L. Callum, D. Cheng, L. Heinrich, B. Kent, T. W.R. Lee, et al. Comprehensive Canadian Review of the Off-Label Use of Recombinant Activated Factor VII in Cardiac Surgery Circulation, July 22, 2008; 118(4): 331 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Bowman, W. E. Uber, M. R. Stroud, L. R. Christiansen, J. Lazarchick, A. J. Crumbley III, J. M. Kratz, J. M. Toole, F. A. Crawford Jr, and J. S. Ikonomidis Use of Recombinant Activated Factor VII Concentrate to Control Postoperative Hemorrhage in Complex Cardiovascular Surgery Ann. Thorac. Surg., May 1, 2008; 85(5): 1669 - 1677. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Dunkley, L. Phillips, P. McCall, J. Brereton, R. Lindeman, G. Jankelowitz, and P. Cameron Recombinant Activated Factor VII in Cardiac Surgery: Experience From the Australian and New Zealand Haemostasis Registry Ann. Thorac. Surg., March 1, 2008; 85(3): 836 - 844. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
